66 Participants Needed

Hydroxychloroquine + Abemaciclib for Breast Cancer

(ABBY Trial)

LB
Overseen ByLauren Bayne, PhD
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Abramson Cancer Center at Penn Medicine
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Breakthrough TherapyThis drug has been fast-tracked for approval by the FDA given its high promise

Trial Summary

What is the purpose of this trial?

This is a Phase II randomized, controlled, open label breast cancer clinical trial. 66 patients will be enrolled. The drugs being studied are hydroxychloroquine (Plaquenil) and abemaciclib (also Verzenio). This research study is testing whether using these drugs to target the disseminated tumor cells in bone marrow can reduce their number or eliminate them. Both hydroxychloroquine and abemaciclib are pills that will be taken twice daily. Both are approved by the FDA

Will I have to stop taking my current medications?

The trial does not specify if you need to stop all current medications, but you cannot take tamoxifen due to interactions with hydroxychloroquine. You can continue adjuvant endocrine and bone modifying agents as per standard care guidelines.

What data supports the effectiveness of the drug combination of Hydroxychloroquine and Abemaciclib for breast cancer?

Research shows that Abemaciclib, when combined with endocrine therapy, is effective in reducing the risk of breast cancer recurrence in patients with hormone receptor-positive, HER2-negative breast cancer. It has also been shown to improve progression-free survival in advanced breast cancer when used as a first-line therapy.12345

What makes the drug combination of Hydroxychloroquine and Abemaciclib unique for breast cancer treatment?

This drug combination is unique because it combines Hydroxychloroquine, which is traditionally used for malaria and autoimmune diseases, with Abemaciclib, a CDK4/6 inhibitor that targets specific proteins involved in cell division. This combination may offer a novel approach for patients with hormone receptor-positive, HER2-negative breast cancer, especially after progression on other CDK4/6 inhibitors.13456

Research Team

Amy S. Clark, MD, MSCE profile ...

Amy Clark

Principal Investigator

Abramson Cancer Center at Penn Medicine

Eligibility Criteria

This trial is for adults who've had invasive breast cancer diagnosed within the last 5 years and have finished primary treatments, except endocrine therapy. They must not show signs of cancer recurrence, be able to take oral meds, and meet specific health criteria like good organ function. Pregnant women or those not using birth control are excluded.

Inclusion Criteria

You have specific characteristics in your breast cancer that put you at a higher risk, such as certain receptor levels or lymph node status.
My breast cancer was confirmed by a biopsy and diagnosed within the last 5 years.
Patients must have completed all primary therapy (definitive surgery, (neo)adjuvant chemotherapy adjuvant radiation and/or Her2-directed therapy) for the index malignancy at least 4 weeks prior to study entry. Prior treatment-related toxicity must be resolved or improving to Grade 1 with the exception of alopecia, Grade 2 endocrine disorders (e.g. adrenal insufficiency or thyroid disorders from prior immunotherapy) controlled on stable replacement therapy for > 1 year, and up to Grade 3 peripheral neuropathy, prior to study enrollment. Concurrent receipt of adjuvant endocrine and bone modifying agents is allowed per standard of care guidelines. Tamoxifen is not allowed due to drug-drug interactions with HCQ. Bone marrow aspirate obtained via research trial UPCC 28115 after completion of therapy (except endocrine therapy) demonstrates detectable DTCs (via IHC). No evidence of recurrent local or distant breast cancer by physical examination, blood tests (CBC, LFTs, Alk Phos), or imaging. Assessment for overt metastatic disease by radiologic testing per institutional guidelines (CT Chest, Abdomen and Pelvis, bone scan, MRI and/or PET/CT) will only be done in patients with DTCs detected on bone marrow aspirate who are being screened for this trial. Age >/= 18 years. ECOG performance status =/< 2. Ability to swallow oral medications. No contraindications to the study medications or uncontrolled medical illness. Adequate bone marrow function as shown by: ANC >/= 1.5 x 10^9/L, Platelets >/= 100 x 10^9/L, Hb >9 g/dL. Adequate liver function as shown by: Serum bilirubin </= 1.5 x ULN, ALT and AST </= 3.0 x ULN, and INR </=1.5. Adequate renal function: serum creatinine </= 1.5 x ULN. Adequate muscle function: creatinine phosphokinase (CPK) </= 2.5 x ULN. Anticoagulation is allowed if target INR =/< 1.5 on a stable dose of warfarin or on a stable dose of anticoagulant for >2 weeks at time of randomization. Ability to provide informed consent

Exclusion Criteria

Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study
I started taking medication for bone health less than 3 months ago.
I am not taking tamoxifen for my hormone-receptor positive breast cancer due to its interaction with hydroxychloroquine.
See 8 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive Abemaciclib and/or Hydroxychloroquine to target disseminated tumor cells in bone marrow

6 months
6 cycles of treatment

Safety Assessment

Incidence of treatment-emergent adverse events during cycle 1 of the safety cohort

4 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Abemaciclib
  • Hydroxychloroquine
Trial OverviewThe study compares hydroxychloroquine (Plaquenil) and abemaciclib (Verzenio), both FDA-approved drugs taken as pills twice daily. It aims to see if these can reduce or eliminate disseminated tumor cells in bone marrow after standard treatment for breast cancer.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: B (Abema + HCQ)Experimental Treatment2 Interventions
Abemaciclib (100 mg or 150 mg BID\*) + Hydroxychloroquine (600 mg BID) \*Abemaciclib dose will be determined by safety cohort
Group II: A (Abema)Experimental Treatment1 Intervention
Abemaciclib (150 mg BID)

Abemaciclib is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as Verzenio for:
  • Hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer
  • HR+, HER2- node-positive early breast cancer
🇪🇺
Approved in European Union as Verzenio for:
  • HR+, HER2- advanced or metastatic breast cancer
  • HR+, HER2- node-positive early breast cancer

Find a Clinic Near You

Who Is Running the Clinical Trial?

Abramson Cancer Center at Penn Medicine

Lead Sponsor

Trials
425
Recruited
464,000+

Abramson Cancer Center of the University of Pennsylvania

Lead Sponsor

Trials
360
Recruited
108,000+

Findings from Research

In a phase III trial, abemaciclib combined with endocrine therapy significantly reduced the risk of breast cancer recurrence in patients with hormone receptor positive (HR+), HER2-negative, node-positive early breast cancer, regardless of prior chemotherapy or tumor characteristics.
The combination treatment was generally well-tolerated, with manageable side effects such as diarrhea, infections, and neutropenia, making it a valuable option for high-risk patients.
Abemaciclib: A Review in Early Breast Cancer with a High Risk of Recurrence.Fung, S., Blair, HA.[2023]
Interim results from the MONARCH3 study show that abemaciclib, a CDK4/6 inhibitor, is an effective first-line treatment for advanced ER-positive, HER2-negative breast cancer.
Patients receiving abemaciclib in combination with letrozole experienced significantly improved progression-free survival compared to those receiving a placebo with endocrine therapy.
First-Line Abemaciclib Effective in ER+ Breast Cancer.[2019]
Abemaciclib combined with endocrine therapy (ET) significantly improves quality-adjusted life years (QALYs) in patients with high-risk hormone receptor positive, HER2-negative early breast cancer, with an increase of 0.99 QALYs compared to ET alone.
The treatment is considered cost-effective in Italy, with an incremental cost-effectiveness ratio of €22,651 per QALY gained, and a 99% likelihood of being cost-effective at a threshold of €30,000 per QALY.
Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2-, node-positive, high-risk early breast cancer in Italy.Davie, A., Traoré, S., Giovannitti, M., et al.[2023]

References

Abemaciclib: A Review in Early Breast Cancer with a High Risk of Recurrence. [2023]
First-Line Abemaciclib Effective in ER+ Breast Cancer. [2019]
Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2-, node-positive, high-risk early breast cancer in Italy. [2023]
MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study. [2022]
A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression. [2023]
Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer. [2020]